

Policy Briefing Summary

City Council



Regarding:	Resolution authorizing the City's participation in the proposed settlements of Opioid-related claims against ALVOGEN, AMNEAL, APOTEX, HIKMA, INDIVIOR, MYLAN, SUN, and ZYDUS (1 of 2 readings)
Staff Contact(s):	Ashley Marshall, Deputy City Manager, John Maddux, City Attorney
Presenter:	Ashley Marshall, Deputy City Manager
Date of Proposed Action:	September 15, 2025

Issue

The City of Charlottesville is eligible for additional Opioid Settlement funding from eight opioid manufacturers under the accepted Virginia Collaborative process.

Background / Rule

A formal communication from the National Opioids Settlements Implementation Administrator went out to all Virginia cities and counties in August 2025 concerning the proposed settlement of opioid-related claims reached against eight opioid manufacturers: Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan, Sun, and Zydus. All litigating localities are required to have their governing bodies approve a resolution pertaining to this additional settlement.

Analysis

Eight additional opioid manufacturers—Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan, Sun, and Zydus—have reached a series of new national settlement agreements. These companies have agreed to pay a combined total of approximately \$720 million to resolve opioid-related claims nationwide.

Our ability to participate in and receive funds from these new settlements is governed by the Virginia Opioid Abatement Fund and Settlement Allocation Memorandum of Understanding, which the City of Charlottesville approved and adopted, affirming that any pending settlement would be subject to that Virginia MOU. These new funds will be administered similarly to those from prior settlements with McKesson, Cardinal Health, AmerisourceBergen, Janssen, Teva, Allergan, CVS, Walgreens, Walmart, and Kroger.

As with prior settlements, states and local governments that want to participate in this 2025 settlement can legally opt in by executing the required participation and release forms, including the proposed resolution, by October 8, 2025. These settlements are part of the ongoing proceedings in the *In re: National Prescription Opiate Litigation, MDL No. 2804 (N.D. Ohio), Case No. 1:17-md-2804*. The City of Charlottesville remains committed to using these funds to combat the opioid crisis and support the health and well-being of our residents.

For more detailed information, including the full settlement agreements and implementation details, please visit the official website: <https://nationalopioidsettlement.com/>

Financial Impact

The City of Charlottesville is eligible to receive a portion of the settlements, with amounts distributed based on participation rates and the allocation formula under the Virginia MOU. There is no impact to

the General Fund, and this funding is restricted to allowable usages as identified by the settlement documents and the Virginia Opioid Abatement Authority.

Recommendation

Pursuant to the City Council's previous approval of similar opioid-related settlements, adopt the attached Resolution approving the County's participation in the proposed settlements of opioid-related claims against Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan, Sun, and Zydus, and authorize the City Manager and City Attorney to execute the necessary documentation to effectuate the City of Charlottesville's participation.

Recommended Motion (if Applicable)

Attachments

1. September 2025 Proposed Settlement Authorization
2. RESOLUTION_ ALVOGEN_ AMNEAL_ APOTEX_ HIKMA_ INDIVIOR_ MYLAN_ SUN_ ZYDUS
3. 2025 Charlottesville Notice National Opioids Settlements for Alvogen, Amneal, Apotex, Hikma, Indivior, Mylan, Sun, Zydus
4. Dec06 2021-Cert. Resolution approving Virginia Opioid MOU